These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15300157)

  • 21. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
    Struck J; Muck P; Trübger D; Handrock R; Weidinger G; Dendorfer A; Dodt C
    J Hypertens; 2002 Jun; 20(6):1143-9. PubMed ID: 12023684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do most antihypertensive agents have a sympatholytic action?
    de Champlain J
    Curr Hypertens Rep; 2001 Aug; 3(4):305-13. PubMed ID: 11470013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial interactions between pharmacological, pathophysiological and hypertension research.
    van Zwieten PA
    J Hypertens; 1999 Dec; 17(12 Pt 2):1787-97. PubMed ID: 10703870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of the sympathetic nervous system in essential arterial hypertension and organ damage].
    Grassi G; Mancia G
    Ann Ital Med Int; 1995 Oct; 10 Suppl():115S-120S. PubMed ID: 8562257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.
    Kamide K; Rakugi H; Higaki J; Okamura A; Nagai M; Moriguchi K; Ohishi M; Satoh N; Tuck ML; Ogihara T
    Am J Hypertens; 2002 Jan; 15(1 Pt 1):66-71. PubMed ID: 11824863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW
    Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.
    Chauvin B; Richer C; Giudicelli JF
    Br J Pharmacol; 1995 Oct; 116(4):2229-36. PubMed ID: 8564253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension.
    Benedict CR
    Curr Hypertens Rep; 1999 Aug; 1(4):305-12. PubMed ID: 10981082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sympathetic activity, blood pressure variability and end organ damage in hypertension.
    Mancia G; Di Rienzo M; Parati G; Grassi G
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S3-8. PubMed ID: 9321734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sympathetic system and hypertension.
    Esler M
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):99S-105S. PubMed ID: 10921528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive drugs and the sympathetic nervous system.
    Del Colle S; Morello F; Rabbia F; Milan A; Naso D; Puglisi E; Mulatero P; Veglio F
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):487-96. PubMed ID: 18030057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat.
    K-Laflamme A; Oster L; Cardinal R; de Champlain J
    Hypertension; 1997 Aug; 30(2 Pt 1):278-87. PubMed ID: 9260993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sympathetic nervous system: role in hypertension and in chronic kidney disease.
    Grassi G; Bertoli S; Seravalle G
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):46-51. PubMed ID: 22080859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy of Hypertension in Chronic Dialysis Patients.
    Georgianos PI; Agarwal R
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):2062-2075. PubMed ID: 27797886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.